1. Psychogenic movement disorders: A crisis for neurology

   • Mark Hallett

   Invited Commentary Pages: 269 - 271

2. Web alert

   News Pages: 272 - 273

3. Tetrabenazine versus placebo for chorea in huntington’s disease

   • John C. Morgan
   • Kapil D. Sethi

   Clinical Trials Report Pages: 277 - 278

4. Ropinirole versus placebo in primary restless legs syndrome

   • John C. Morgan
   • Kapil D. Sethi

   Clinical Trials Report Pages: 278 - 280

5. Update on huntington’s disease

   • Sarah B. Berman
   • J. Timothy Greenamyre

   OriginalPaper Pages: 281 - 286

6. PARK8 LRRK2 parkinsonism

   • Kristoffer Haugarvoll
   • Zbigniew K. Wszolek

   OriginalPaper Pages: 287 - 294

7. Preclinical diagnosis of parkinson’s disease: Are we there yet?

   • Andrew Siderowf
   • Matthew B. Stern

   OriginalPaper Pages: 295 - 301

8. Impulse control disorders in parkinson’s disease

   • Daniel Weintraub
   • Marc N. Potenza

   OriginalPaper Pages: 302 - 306

9. Autoantibodies: A novel etiology for refractory epilepsy?

   • Carl W. Bazil
   • Lawrence J. Hirsch

   Clinical Trials Report Pages: 309 - 310

10. Antiepileptic therapy in patients with central nervous system malignancies

    • Glen H. J. Stevens

    OriginalPaper Pages: 311 - 318

11. Cognitive functioning following epilepsy surgery

    • Marla J. Hamberger
    • Evan B. Drake

    OriginalPaper Pages: 319 - 326

12. Magnetoencephalography in epilepsy: tailoring interpretation and making inferences

    • Joshua Cappell
    • Catherine Schevon
    • Ronald G. Emerson

    OriginalPaper Pages: 327 - 331

13. State of the ketogenic diet(s) in epilepsy

    • Jennifer Huffman
    • Eric H. Kossoff

    OriginalPaper Pages: 332 - 340

14. Antiepileptic drugs and neurodevelopment

    • Gholam K. Motamedi
    • Kimford J. Meador

    OriginalPaper Pages: 341 - 346

15. Use of complementary and alternative medicine in epilepsy

    • Valeria Ricotti
    • Norman Delanty

    OriginalPaper Pages: 347 - 353